{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:09:37Z","timestamp":1761520177670,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013213","name":"ARUP Institute for Clinical and Experimental Pathology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013213","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clcc.2019.04.005","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T20:41:55Z","timestamp":1556829715000},"page":"e280-e286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Prevalence of DPYD*9A (c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis"],"prefix":"10.1016","volume":"18","author":[{"given":"Anu Singh","family":"Maharjan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwendolyn A.","family":"McMillin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girijesh Kumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur E.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Joel","family":"Hosein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moh\u2019d","family":"Khushman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 4","key":"10.1016\/j.clcc.2019.04.005_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.6-suppl_4-3","article-title":"The evolution of fluoropyrimidine therapy: from intravenous to oral","volume":"6","author":"Hoff","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2019.04.005_bib2","doi-asserted-by":"crossref","first-page":"e0174280","DOI":"10.1371\/journal.pone.0174280","article-title":"Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer","volume":"12","author":"Huang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2019.04.005_bib3","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1093\/annonc\/mdr031","article-title":"Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients","volume":"22","author":"Cassidy","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2019.04.005_bib4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1634\/theoncologist.11-4-325","article-title":"Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer","volume":"11","author":"Ershler","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2019.04.005_bib5","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2019.04.005_bib6","first-page":"22","article-title":"Considerations for use of fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients","volume":"1","author":"Werschler","year":"2008","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"key":"10.1016\/j.clcc.2019.04.005_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/FPC.0b013e32833c6107","article-title":"PharmGKB summary: fluoropyrimidine pathways","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clcc.2019.04.005_bib8","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2019.04.005_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","article-title":"Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity","volume":"313","author":"Tuchman","year":"1985","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2019.04.005_bib10","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.clcc.2019.04.005_bib11","first-page":"832","article-title":"Dihydropyrimidine dehydrogenase deficiency (Dpd) in GI malignancies: experience of 4 years","volume":"23","author":"Saif","year":"2007","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.clcc.2019.04.005_bib12","doi-asserted-by":"crossref","first-page":"dju298","DOI":"10.1093\/jnci\/dju298","article-title":"DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)","volume":"106","author":"Lee","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2019.04.005_bib13","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/1078-0432.CCR-06-0747","article-title":"Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.04.005_bib14","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","article-title":"Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance","volume":"5","author":"Morel","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clcc.2019.04.005_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1258\/000456303321016150","article-title":"Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency","volume":"40","author":"van Kuilenburg","year":"2003","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.clcc.2019.04.005_bib16","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","article-title":"Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity","volume":"74","author":"Offer","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.clcc.2019.04.005_bib17","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/pgs.13.116","article-title":"DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis","volume":"14","author":"Terrazzino","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clcc.2019.04.005_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FPC.0000000000000197","article-title":"Association between DPYD c.1129-5923 C>G\/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)","volume":"26","author":"Lee","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clcc.2019.04.005_bib19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s004390050637","article-title":"Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W","volume":"101","author":"Vreken","year":"1997","journal-title":"Hum Genet"},{"key":"10.1016\/j.clcc.2019.04.005_bib20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1023\/A:1005357307122","article-title":"Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene","volume":"20","author":"Vreken","year":"1997","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.clcc.2019.04.005_bib21","doi-asserted-by":"crossref","first-page":"10393","DOI":"10.1007\/s13277-016-4908-2","article-title":"DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia","volume":"37","author":"Zhao","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.clcc.2019.04.005_bib22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00280-015-2698-7","article-title":"Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy","volume":"75","author":"Joerger","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clcc.2019.04.005_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF02698048","article-title":"DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients","volume":"24","author":"Zhang","year":"2007","journal-title":"Med Oncol"},{"key":"10.1016\/j.clcc.2019.04.005_bib24","first-page":"E45","article-title":"DPYD, TYMS and MTHFR genes polymorphism frequencies in a series of Turkish colorectal cancer patients","volume":"8","author":"Amirfallah","year":"2018","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.clcc.2019.04.005_bib25","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2009.21.7943","article-title":"Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741","volume":"28","author":"McLeod","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.04.005_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clcc.2019.04.005_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4149\/neo_2009_04_303","article-title":"Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy","volume":"56","author":"Kleibl","year":"2009","journal-title":"Neoplasma"},{"key":"10.1016\/j.clcc.2019.04.005_bib28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2217\/pgs.09.28","article-title":"Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment","volume":"10","author":"Amstutz","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clcc.2019.04.005_bib29","first-page":"125","article-title":"Genetic variability and chemotoxicity of 5-fluorouracil and cisplatin in head and neck cancer patients: a preliminary study","volume":"137","author":"Dhawan","year":"2013","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.clcc.2019.04.005_bib30","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1158\/1078-0432.CCR-10-2209","article-title":"Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer","volume":"17","author":"Deenen","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2019.04.005_bib31","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4103\/0973-1482.148685","article-title":"DPYD*2A\/*5A\/*9A and UGT1A1*6\/*28 polymorphisms in Chinese colorectal cancer patients","volume":"12","author":"Li","year":"2016","journal-title":"J\u00a0Cancer Res Ther"},{"key":"10.1016\/j.clcc.2019.04.005_bib32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clcc.2019.04.005_bib33","doi-asserted-by":"crossref","first-page":"416","DOI":"10.21037\/jgo.2018.02.03","article-title":"Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines","volume":"9","author":"Khushman","year":"2018","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.clcc.2019.04.005_bib35","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2002.20.6.1491","article-title":"Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer","volume":"20","author":"Sloan","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2019.04.005_bib36","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cncr.20878","article-title":"Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma","volume":"103","author":"Chansky","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2019.04.005_bib37","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002819301148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002819301148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:05:15Z","timestamp":1761519915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002819301148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1533002819301148"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2019.04.005","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Prevalence of DPYD*9A (c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2019.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}